Bisartans exhibit dual antihypertensive and antiviral abilities through angiotensin type 1 receptor (AT1R) blockage and inhibiting entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein through destabilization of the angiotensin-converting enzyme-2 (ACE2) receptor binding domain complex, and thus preventing coronavirus 2019 (COVID-19) [38,39,40,41]. Here, ACE2 is linked to COVID-19.